RIGL · NASDAQ
Rigel Pharmaceuticals, Inc.
$51.25 +0.47 (+0.93%)
Company overview
Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib, which is in Phase III clinical trials for warm autoimmune hemolytic anemia and for the treatment of hospitalized COVID-19 patients. Additionally, the company is developing R289, an oral interleukin receptor-associated kinase 1/4 inhibitor in Phase I trials for autoimmune, inflammatory, and hematology-oncology diseases, and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed Phase I trials for autoimmune and inflammatory diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $957M
- Employees
- 162
- Headquarters
- South San Francisco, CA
- Website
- rigel.com
- CEO
- Raul R. Rodriguez
- Listed
- November 29, 2000
- P/E
- 2.55
- Dividend yield
- 0.00%
Company financials
- Revenue
- $300M
- Gross profit
- $280M
- Operating income
- $125M
- EBITDA
- $131M
- Net income
- $364M
- EPS
- $20.07
- Total assets
- $505M
- Total debt
- $45.7M
- Gross margin
- 93.39%
- Net margin
- 121.51%
- Earnings yield
- 39.16%
No geographic segmentation.
Showing FY 2025
RIGL
1D
NASDAQ
O50.26H51.27L50.06C50.78+0.23 (+0.45%)Vol55.13K